





































Effect of Eye Spray Phospholipid Concentration on the Tear Film
and Ocular Comfort
Heiko Pult, Ph.D., Farzana S. Khatum, Sonia Trave-Huarte, B.Sc., and James S. Wolffsohn, Ph.D.
Objectives: To evaluate the effect of eye spray phospholipid concentration
on symptoms and tear film stability.
Methods: High-concentration (Tears Again, Optima Pharma GmbH,
Hallbergmoos, Germany) and low-concentration (Ocuvers, Innomedis
AG, Germany) phospholipid eye sprays were sprayed onto the closed
eyelids of 30 subjects (33.261.8 years; 20 women) in a multicentered,
prospective, crossover study. Ocular comfort (visual analog scale) and non-
invasive tear film stability (NIBUT) of each eye were evaluated before
application (along with the Ocular Surface Disease Index), 10 min after
application, and 30 min after application.
Results: Comfort (high concentration: 68.5616.4 vs. low concentration:
70.7614.5 phospholipid) and NIBUT (high concentration: 11.564.6 sec
vs. low concentration: 11.266.0 sec phospholipid) were not different
(P.0.3) between sprays before application, but comfort (by 12 points,
P¼0.001) and NIBUT (by 5 sec, P¼0.016) were significantly better with
a high-concentration phospholipid spray at both 10 min and 30 min time
points than those with the low-concentration phospholipid spray.
Conclusions: The liposomal eye spray with higher concentration of phospho-
lipids significantly improved ocular comfort and tear film stability in contrast to
the eye spray with lower concentration of phospholipids, hence practitioners
need to choose an appropriate eye spray to maximize the patient benefit.
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D ry eye is a common disease, described as aqueous-deficientand/or evaporative dry eye,1 the latter being the most com-
mon type (78%).2,3 The lipid layer of the tears plays an important
role in inhibiting tear film evaporation and in spreading the tears
across the ocular surface.4 The lipid layer is a complex structure
with an inner polar layer, interfacing with the aqueous phase and
reducing surface tension, and a thicker, outer, nonpolar layer.5 The
lipid layer stabilizes the tear film providing a surface tension
decrease and a 90% to 95% aqueous evaporation reduction.6,7
Phospholipid liposomal spray is suggested to improve the polar
properties of the lipid layer (such as its surface tension and solubility),
enhancing lipid spread over the tear film.8–14 The spray is applied to
the closed eyelids and supplements phospholipid liposomes to the lid
margins, where the phospholipids mix with the present lipid reservoir
from the meibomian glands. Improvements in symptomatology, visual
acuity, lipid layer thickness, tear film stability, eyelid margin inflam-
mation, tear production, and lid parallel conjunctival folds have been
documented with the use of the original liposomal spray in patients
with dry eye.8–15 However, as other sprays have become available
with different concentrations of phospholipids, contradictory studies
have been published on their relative effectiveness.14,16,17 These stud-
ies were based on a contralateral eye design, limiting the accurate
reporting of symptomology.18 It is well established that normal eyes
do not function as independent units, but rather there is cross-
communication between right and left eyes.18 Hence this study aimed
to determine the relative effectiveness of two liposomal eye sprays
with different concentration of phospholipids on dry eye symptoms
and tear film stability in a multicentered, prospective, crossover trial.
METHODS
Based on laboratory analyses of phospholipid concentrations of
different sprays, one high-concentration and one low-concentration
phospholipid eye spray was selected (Table 1).
Participants gave written informed consent before participating
in the study. Ethical approval was given by the Research Ethics
Committee of Aston University. All procedures were conducted in
accordance with the Declaration of Helsinki (1983). Potential
participants were excluded if they were contact lens wearers or had
worn lenses within the last year, were younger than 18 years, had
any ocular surface defect or pathology, were pregnant, or had used
any ocular medications or drops on the study visit days.
The high-concentration (Tears Again Sensitive, Optima Phar-
mazeutische GmbH, Hallbergmoos, Germany) and low-
concentration phospholipid (Ocuvers, Innomedis AG, Germany)
formulations were sprayed from a distance of 10 cm onto each
closed eyelids of 30 participants in a multicentered, prospective,
double-blind, crossover study. Participants were randomized as to
which spray they received bilaterally first, and there was a gap of
24 to 120 hr between trials.
Before application, each participant’s symptoms were evaluated
using the Ocular Surface Disease Index (OSDI) questionnaire.19 Total
OSDI scores were calculated as recommended by Schiffman et al.20
Ocular comfort (“How is the current comfort of your eye?”) of each
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eye was reported on a visual analog scale (100 ¼ perfect) and non-
invasive tear breakup time (NIBUT) was determined using a Tear-
scope Plus (Keeler Ltd, Windsor, United Kingdom) with a fine grid
insert21 before and again 10 min and 30 min after application of the
sprays. Noninvasive tear breakup time was the time measured, in
seconds, between the full opening of the eyelids after a complete blink
and the first break in the tear film. Three consecutive readings were
evaluated, and the median noted. Both the observer and the subject
were masked from the previous results throughout the study. As both
sprays are CE marked, have been commercially available for many
years and have been evaluated in different independent stud-
ies,8,10,13–17,22 the safety of the spray was not part of the study design.
Statistical Analyses
The distribution of the data was tested using a Shapiro–Wilk test.
As all the data were significantly different from a normal distribu-
tion, differences between treatments at each time point between arms
were analyzed by Wilcoxon signed-rank tests and between consec-
utive measurements by Friedman tests (SPSS Statistics for Windows,
version 20, IBM Corp., Armonk, NY). Thirty participants were
recruited to allow a 90% power comparison based on previously
reported noninvasive breakup time repeatability [21] to detect a
difference of 2 sec (effect size¼0.62; a¼0.05; 1-b¼0.90; G*Power
v3.1.9.4: Franz Faul, University Kiel, Germany).
RESULTS
The 30 participants (aged 33.261.8 years; 20 women) had a
mean OSDI score of 13.2614.3 (SD). Comfort scores (Friedman
test; P¼0.003) and NIBUT (P¼0.017) significantly increased after
application of the high-concentration phospholipid spray, but
(Friedman test; P¼0.003), not when using the low-concentration
phospholipid spray (P¼0.424 and P¼0.839, respectively).
When comparing both arms (high-concentration and low-
concentration phospholipid sprays), comfort scores were not
statistically different before treatment (Wilcoxon test; P¼0.794)
but were significantly better for the high-concentration phospho-
lipid spray at the 10 min (P¼0.006) and 30 min (P¼0.001) time
points (Fig. 1 and Table 2). Noninvasive tear breakup time was
also not statistically different between arms before treatment
(P¼0.934) but was significantly better for the high-concentration
phospholipid spray at the 10 min (P¼0.038) and 30 min (P¼0.027)
time points (Fig. 2 and Table 2). No complications were reported
from the use of either spray.
DISCUSSION
This study aimed to determine the relative effectiveness of two
liposomal eye sprays with different concentration of phospholipids
on dry eye symptoms and tear film stability. Based on laboratory
analyses, the concentration of the phospholipids of the high-
concentration phospholipid spray was 8 times higher than that of
the low-concentration phospholipid, but otherwise the sprays were
similar in the delivery device; hence, the impact of lipid
concentration on comfort and tear stability could be assessed.
Use of the high-concentration phospholipid spray resulted in a
significant effect on symptoms (reduction) and tear film stability
(increase), whereas the lower-concentration phospholipid spray did
not have any measurable effect, in the same participants. The
findings of this study are in accordance with findings of many
research groups in contact lens wearers and nonlens wear-
ers.8,10,13–15,17,23 Previous studies have demonstrated that the
high-concentration phospholipid spray improves tear film parame-
ters from less than 10 min to 90 min after application.8,14 The
converse findings of a single comparative contralateral trial, where
a low-concentration phospholipid spray outperformed the high-
concentration competitor, are hard to explain.16 The main limita-
tion of this study was the single use of each spray and not exam-
ining a population with a wider range of dry eye symptoms.
However, a marked improvement in both dryness symptoms and
tear film stability was found with the concentration of the phos-
pholipid, which would be expected to increase with more frequent
use of the spray and in a population with drier eyes. In case of eyes
with aqueous deficiency, phospholipids in conjunction with artifi-
cial tears might be beneficial and deserves future investigation.
In dry eye, increased evaporation of the tear film results in
hyperosmolarity of the tear film, initiating a cascade of inflamma-
tory processes resulting in epithelium damage, mucin deficiency,
and reduced wettability of the cornea.24,25 This has been identified
as the core mechanism of dry eye.24,26 Any improvement of the
Table 1: Laboratory Analyses of Two Different Liposomal Eye Sprays (Spectral Service GmbH, Cologne, Germany; Analyses Certificate DIA76896-1,
02. and DIA74607-3; 2018)
Product Phospholipids Weight Percent Concentration
Ocuvers Spray hyaluron Phosphatidylcholine 0.04 0.4 mg/mL
Unidentifiable phospholipids 0.08 0.8 mg/mL
In total 0.12 1.2 mg/mL
Tears Again Sensitive Phosphatidylcholine 0.95 9.5 mg/mL
2-Lysophosphatidylcholine 0.03 0.3 mg/mL
In total 0.98 9.8 mg/mL
FIG. 1. Mean comfort scores (on a 100 point, visual analog scale)
and standard error over the observation time of 0 to 30 min (high-
concentration (HC) and low-concentration (LC) phospholipid spray).
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lipid layer suppresses the vicious cycle of dry eye disease, thus
improving the epithelium and consequently the mucin layer and
wettability of the cornea.7 This might be an important factor to be
considered in the long-term treatment of patients with the evapo-
rative form of dry eye.
This study showed that a high-concentration phospholipid spray
improved tear film stability and also enhanced ocular comfort.
Phospholipids are recognized to be important components within
the tear film. They are vital in surface monolayer formation and for
surfactant properties. Ninety-two percent of the meibum consists of
neutral lipids, and the remaining 8% of polar lipids.27 The polar
lipids consist of 70% phospholipids; the most predominant of
which is phosphatidylcholine. Deficiency of these components pre-
vents formation of a stable, continuous lipid layer, which, in turn,
causes an increased tear evaporation rate.27,28 The liposomal spray
Tears Again is a tear film supplement containing phosphatidylcho-
line derived from highly purified soy lecithin. The major phospho-
lipid, phosphatidylcholine, is delivered in a stable form of
liposomes to the closed eyelid. From there, they migrate, with
blinking, across the eyelid margins to combine with the tear film.14
Improvement of tear film stability after application of a spray with
a higher concentration of phosphatidylcholine confirms the positive
effect this phospholipid has on the tear film.
CONCLUSION
The liposomal eye spray with a high concentration of phospho-
lipids significantly improved ocular comfort and tear film stability
in contrast to the eye spray with a lower concentration of
phospholipids, which had no effect; hence, practitioners need to
choose an appropriate phospholipid eye spray to maximize the
benefit to patients with dry eyes due to a deficient lipid layer.
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